Navigation Links
Three-Year Clinical Outcomes from Use of Genous™ Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy
Date:11/8/2011

aspirin administration was indefinite.

"For patients treated with Genous, our typical prescription of dual antiplatelet therapy (DAPT) is 30 days," said Robbert de Winter, M.D., Ph.D., of the Academic Medical Center, Amsterdam. "In this large, unselected patient population, there was also a segment of patients who were contraindicated to long-term DAPT and thus received less than 30 days of DAPT. For this reason, it was particularly striking there were only two cases of early stent thrombosis and that no thrombosis was observed after one month through the three year follow up, attesting to the excellent safety profile of Genous in a real world setting."

Please visit the following link to hear Prof. de Winter discuss these data: http://youtu.be/qFLGkc2PaXg.

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 7,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, th
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
3. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
4. MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices
5. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
6. Comfort Medical Supply, LLC Ranks No. 461 on the 2010 Inc. 500 with Three-Year Sales Growth of 649%
7. Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600%
8. Three-Year Follow-Up Data Confirm Safety and Survival Benefit in Chinese Liver Failure Patients Treated With ELAD® Bioartificial Liver
9. Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytrens Contracture in E-poster at ASSH Meeting
10. MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BUFFALO, N.Y. , Dec. 24, 2014 ... been dosed with KX2-361 at Roswell Park Cancer Institute. ... a small molecule drug that has shown potent inhibitory ... lines, including those that are resistant to Temozolomide (T98G), ... malignant glioma. In a well-established brain tumor mouse model, ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... FRANKFORT, Ky., Oct. 7, 2011 The Consumer ... the Kentucky General Assembly to adopt a new ... and abuse, the Meth Offender Registry Block List. ... from purchasing medicines containing pseudoephedrine (PSE) –medicines like ...
... Pharmaceuticals, Inc. (NYSE: WPI ) today confirmed ... an Abbreviated New Drug Application (ANDA) with the U.S. ... Morphine Sulfate and Naltrexone Hydrochloride Extended-release Capsules 30 mg/1.2 ... mg, and 100 mg/4 mg.  Watson,s Morphine Sulfate and ...
Cached Medicine Technology:Consumer Group Advances Alternative to Prescription Mandate 2Consumer Group Advances Alternative to Prescription Mandate 3Watson Confirms EMBEDA(R) Patent Challenge 2Watson Confirms EMBEDA(R) Patent Challenge 3
(Date:12/24/2014)... Dr. Svetlana Gomer, MGS Tewksbury Dental, ... gathered with US Marines on November 14, 2014 for ... the Toys for Tots Literacy Program. This year’s ... books and audio books for the Toys for Tots ... Christmas. It represents another major strike in the battle ...
(Date:12/24/2014)... 2014 The report offers details on ... various market dynamics such as the key trends, the ... wait time for U.S. sports medicine, the impact of ... the challenges faced by the market. , Browse report ... The report also provides an overview of the global ...
(Date:12/24/2014)... Verde Pointe Dental Associates 2014 Ugly Holiday ... years homemade Christmas sweater lit up, but this years overall ... is Tandy Wilson for the second year in a row. ... Kimmerling DDS. "She took pictures of the entire staff and ... , "Every year I enjoy stopping by the dental ...
(Date:12/24/2014)... Dental implants benefit millions of individuals ... They offer the strongest and most secure hold for ... of tooth replacement. They will never slip out of ... for support, and they prevent the jaw from shrinking ... they are not suitable candidates for dental implants because ...
(Date:12/24/2014)... 24, 2014 Attorneys handling talcum powder ... update to their website, the Talcum Powder Ovarian ... talcum powder class action lawsuits and ovarian cancer claims. ... ovarian cancer updates at their website, which serves as ... ovarian cancer claims are not the same as class ...
Breaking Medicine News(10 mins):Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Verde Pointe Dental Associates Announces the 2014 Ugly Sweater Holiday Contest Winner 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4
... University of Texas, offer some valuable advice on how to ... essential for healthy bones and teeth, and helps prevent osteoporosis ... helps the body produce vitamin D.// Just10 to 15 minutes ... But be warned many factors can reduce sunlight exposure, such ...
... with transplanted hearts from female donors, the proof is the ... at least somewhat by recruiting cells from elsewhere in the ... or dead, they could not be replaced or repaired by ... is found only in men, researchers determined that the female ...
... oxygen therapy at home reduces hospitalisation in those with lung ... the effects of oxygen on 200 patients with smoker's lungs// ... was begun in an outpatient clinic, then continued at home. ... a day, proved to be beneficial. The patients had a ...
... study, a combined scan identifies unstable areas of plaque in ... the future. Fatty deposits, known as plaque, set the scene ... - begins many years before any symptoms occur.// The plaque ... a clot which will then cause a heart attack. ...
... recent study by researchers at the University of Texas, have ... cancer.Omega-3 fatty acids, which are found in fish oil, have ... that the omega-3s block a molecule called protein kinase C ... division. ,In this study, genetically-modified mice, which produce ...
... suggested by researchers to relieve chronic headaches. Botox injections ... not relieved by conventional medication. Botox is shorthand for ... to man. However, it does have some benign uses ... out wrinkles in cosmetic surgery. Now researchers at the ...
Cached Medicine News:
0.5 mm wide x 1.5 mm long. Angled 20 degrees. Octagonal handle....
2 mm wide curved tip. Round handle....
8 mm downcutting Royce blade. Angled shaft. 60 mm from angle to tip....
3 mm disposable Lance blade. Can fit in to the N0521 Storz handle....
Medicine Products: